Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • CD8-Positive T-Lymphocytes
  • Chromatin
  • Neoplasms

abstract

  • Thyroid dysfunction during pembrolizumab treatment of NSCLC is common and is characterized by early-onset, frequently preceded by transient hyperthyroidism, closely associated with anti-thyroid antibodies, and may be associated with improved outcomes. The presence of antibody-mediated toxicity in T-cell-directed therapy suggests an under-recognized impact of PD-1 biology in modulating humoral immunity.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdw640

PubMed ID

  • 27998967

Additional Document Info

start page

  • 583

end page

  • 589

volume

  • 28

number

  • 3